PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
9.45%
Growth of 9.45% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
9.80%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.05%. Jim Chanos would check for structural cost disadvantages.
8.06%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 0.08%. Joel Greenblatt would investigate competitive advantages.
-1.27%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.52%
Other expenses change of 3.52% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
6.21%
Operating expenses growth 1.25-1.5x Medical - Pharmaceuticals median of 4.95%. Guy Spier would scrutinize spending.
9.17%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 3.36%. Jim Chanos would check for waste.
54.55%
Interest expense change of 54.55% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
6.12%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 2.09%. Jim Chanos would check for overinvestment.
11.35%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
1.74%
Margin change of 1.74% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
17.38%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
7.25%
Margin change of 7.25% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-15.45%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
14.37%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
4.50%
Pre-tax margin growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
-58.64%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
50.76%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
37.75%
Net margin growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
50.77%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
50.77%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.